Trials / Recruiting
RecruitingNCT05955196
Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 115 (estimated)
- Sponsor
- Institut Paoli-Calmettes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses structure-based drug design to create selective and potent small molecule inhibitors of SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity than CD47-targeting antibodies. . In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of tumors, we propose to use organoids derived from biopsies of patients with colon cancer. Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an accurate in vitro model of complex tumor immune interaction for the evaluation of immunotherapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | BLOOD AND TUMOR | sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2025-01-09
- Completion
- 2027-01-09
- First posted
- 2023-07-21
- Last updated
- 2024-10-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05955196. Inclusion in this directory is not an endorsement.